[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-341585-105":59,"doc-detail-341585-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","advances-in-non-small-cell-lung-cancer-current-insights-and-future-directions-review","Advances in Non-Small Cell Lung Cancer - Current Insights and Future Directions - Review","","Non-small cell lung cancer (NSCLC) remains the leading cause of cancer mortality worldwide, driving sustained efforts to improve diagnosis and care. This review synthesizes recent breakthroughs and emerging trends, emphasizing progress in diagnostic approaches through advanced imaging and molecular biomarker use to support earlier detection and personalized treatment selection. It also highlights gains in patient outcomes enabled by targeted therapies and immunotherapies, while addressing ongoing barriers related to access and treatment costs for advanced disease. Potential future directions include CAR-T cell therapy and oncolytic viruses.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/advances-in-non-small-cell-lung-cancer-current-insights-and-future-directions-review/341585/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/advances-in-non-small-cell-lung-cancer-current-insights-and-future-directions-review/341585.png","ImageObject",300,407,{"name":92,"@type":93},"Ezra","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-04","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":24},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What are the major diagnostic advances discussed for NSCLC?","Question",{"text":112,"@type":113},"The review highlights improved imaging technologies and the growing use of molecular biomarkers to strengthen early detection and guide personalized treatment decisions.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"Which treatment approaches have recently improved outcomes for advanced NSCLC?",{"text":117,"@type":113},"It emphasizes advances in targeted therapies and immunotherapies, which have contributed to better patient outcomes and new hope for advanced NSCLC.",{"name":119,"@type":110,"acceptedAnswer":120},"What challenges remain despite progress in NSCLC care?",{"text":121,"@type":113},"Access limitations and the associated costs of advanced treatments remain persistent challenges, even after recent improvements.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},341585,1791423342,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":24,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":26,"preview_page_count":19,"preview_urls":145},1099514068035,"https://ap-avatar.wpscdn.com/davatar_276721f389ce27ea32af1340a28f341c","Review  \nAdvances in Non-Small Cell Lung Cancer: Current Insights and Future Directions  \nPankaj Garg 1, Sulabh Singhal 2, Prakash Kulkarni 3, David Horne 4, Jyoti Malhotra 3, Ravi Salgia 3 and Sharad S. Singhal 3, *  \nCitation: Garg, P.; Singhal, S.;  \nKulkarni, P.; Horne, D.; Malhotra, J.; Salgia, R.; Singhal, S.S. Advances in Non-Small Cell Lung Cancer: Current Insights and Future Directions. J. Clin. Med. 2024, 13, 4189. [https://doi.org/](https://doi.org/)[ ](https://doi.org/)[10.3390/jcm13144189](10.3390/jcm13144189)  \nAcademic Editor: Athina N. Markou  \nReceived: 17 June 2024  \nRevised: 11 July 2024  \nAccepted: 17 July 2024  \nPublished: 18 July 2024  \nCopyright: © 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license ([https://](https://)[ ](https://)[creativecommons.org/licenses/by/](creativecommons.org/licenses/by/)[ ](creativecommons.org/licenses/by/)[4.0/](4.0/)) .  \n1 Department of Chemistry, GLA University, Mathura 281406, Uttar Pradesh, India  \n2 Department of Internal Medicine, Drexel University College of Medicine, Philadelphia, PA 19104, USA  \n3 Departments of Medical Oncology & Therapeutics Research, Beckman Research Institute of City of Hope, Comprehensive Cancer Center and National Medical Center, Duarte, CA 91010, USA  \n4 Departments of Molecular Medicine, Beckman Research Institute of City of Hope, Comprehensive Cancer Center and National Medical Center, Duarte, CA 91010, USA  \n* Correspondence: [ssinghal@coh.org](ssinghal@coh.org); Tel.: +1-626-218-4238  \nAbstract: The leading cause of cancer deaths worldwide is attributed to non-small cell lung cancer (NSCLC), necessitating a continual focus on improving the diagnosis and treatment of this disease. In this review, the latest breakthroughs and emerging trends in managing NSCLC are highlighted. Major advancements in diagnostic methods, including better imaging technologies and the utilization of molecular biomarkers, are discussed. These advancements have greatly enhanced early detection and personalized treatment plans. Significant improvements in patient outcomes have been achieved by new targeted therapies and immunotherapies, providing new hope for individuals with advanced NSCLC. This review discusses the persistent challenges in accessing advanced treatments and their associated costs despite recent progress. Promising research into new therapies, such as CAR-T cell therapy and oncolytic viruses, which could further revolutionize NSCLC treatment, is also highlighted. This review aims to inform and inspire continued efforts to improve outcomes for NSCLC patients globally, by offering a comprehensive overview of the current state of NSCLC treatment and future possibilities.  \nKeywords: non-small cell lung cancer (NSCLC); lung cancer diagnosis; targeted therapies; genetic profiling; therapeutic resistance; CAR-T cell therapy  \n1. Introduction  \nNon-small cell lung cancer (NSCLC) is a significant global health issue because it occurs frequently and has a high death rate. It makes up about 85% of all lung cancer cases, making it the most common form of lung cancer [1] . Recent World Health Organization (WHO) statistics indicate that lung cancer is the leading cause of cancer-related deaths worldwide, with around 1.8 million people dying from it each year [2] . The occurrence of NSCLC varies around the world due to differences in smoking habits, environmental factors, and healthcare quality. In developed countries, NSCLC cases are slowly decreasing thanks to successful anti-smoking campaigns and laws [3] . However, in developing countries, NSCLC cases are rising due to higher smoking rates and growing industrialization. Smoking is the main cause of NSCLC, accounting for about 85% of lung cancer cases. Tobacco smoke contains many carcinogens that damage DNA, causing genetic mutations and cancer. The risk of NSCLC is closel","cbCaimwg0tQFCTxW","https://ap.wps.com/l/cbCaimwg0tQFCTxW","pdf",1659619,24,"English","# Introduction\n## Risk factors and epidemiology\n## Diagnostic and molecular subtypes","[{\"question\":\"What are the major diagnostic advances discussed for NSCLC?\",\"answer\":\"The review highlights improved imaging technologies and the growing use of molecular biomarkers to strengthen early detection and guide personalized treatment decisions.\"},{\"question\":\"Which treatment approaches have recently improved outcomes for advanced NSCLC?\",\"answer\":\"It emphasizes advances in targeted therapies and immunotherapies, which have contributed to better patient outcomes and new hope for advanced NSCLC.\"},{\"question\":\"What challenges remain despite progress in NSCLC care?\",\"answer\":\"Access limitations and the associated costs of advanced treatments remain persistent challenges, even after recent improvements.\"}]","Advances in Non-Small Cell Lung Cancer - Current Insights and Future Directions - Review | PDF",1790042674,[146,150,154,158],{"page_no":8,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/e855191ea970a4a5125a40d4a2114e15.webp",983,1390,{"page_no":14,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/c29aeb56db5f7aa3ec860dc468ad3b7d.webp",982,1388,{"page_no":81,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/30428ae6c008e8d8a8adf2c362d30cbb.webp",981,1387,{"page_no":19,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/e7d5f4acf3aa608008d6f74e0d9addc3.webp",980,1385]